Publications by authors named "O Akre"
Objective: The aim of this study is to evaluate treatment patterns and long-term oncological outcomes of patients with locally advanced prostate cancer (LAPCa).
Patients And Methods: This is a population-based study including LAPC (cT3-4, M0) patients from the Stockholm region (Sweden). A sub-analysis was performed in men treated with primary cystoprostatectomy or total pelvic exenteration (TPE) for cT4 prostate cancer (PCa).
Background: Multicenter precision oncology real-world evidence requires a substantial long-term investment by hospitals to prepare their data and align on common Clinical Research processes and medical definitions. Our team has developed a self-assessment framework to support hospitals and hospital networks to measure their digital maturity and better plan and coordinate those investments. From that framework, we developed PRISM for Cancer Outcomes: PR: agmatic I: nstitutional S: urvey and benchM: arking.
View Article and Find Full Text PDFArticle Synopsis
- - The SWENOTECA-MIR study evaluates the effectiveness of miR-371a-3p as a new marker for detecting viable tumors in metastatic germ cell tumor patients undergoing retroperitoneal lymph node dissection (RPLND).
- - In the study of 114 patients, miR-371a-3p showed mixed results, with better performance in seminoma patients than in nonseminomas, particularly before chemotherapy.
- - Overall, while miR-371a-3p demonstrated high specificity in certain groups, its overall sensitivity, especially post-chemotherapy, was low, highlighting potential limitations in using it as a reliable marker for viable tumor detection.
Background And Objective: There is an unmet need to avoid long-term morbidity associated with standard cytotoxic treatment for low-volume metastatic seminoma. Our aim was to assess the oncological efficacy and surgical safety of retroperitoneal lymph node dissection (RPLND) as treatment in a population-based cohort of metastatic seminoma patients with limited retroperitoneal lymphadenopathy.
Methods: Sixty-two seminoma patients in Norway and Sweden were included in the cohort from 2019 to 2022.